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Abstract  Diabetes  mellitus  (DM)  is  a  metabolic  disorder  that  causes  chronic  hyperglycemia
with disturbances  in  the  metabolism  of  carbohydrates,  fats  and  proteins,  and  alterations  in
microcirculation.  We  evaluate  the  criteria  for  the  interpretation  of  the  oral  glucose  tolerance
test (OGTT)  in  the  Hospital  Nacional  Docente  Madre-Nin˜o  ‘‘San  Bartolomé’’  in  Lima,  Peru,  and
determine  the  percentages  of  pre-diabetic  patients,  diabetics  that  should  not  be  included  in  the
test, and  those  with  alterations  in  their  glucose  curve  during  the  biochemical  determinations.
To this  purpose,  a  non-experimental,  prospective  cross-sectional  analytic  study  was
performed  in  1271  patients,  included  in  the  study  to  comply  with  the  guidelines  and  recommen-
dations  of  the  ADA  and  the  CLSI  POCT12-A3  guide,  which  were  processed  in  the  Biochemical
Autoanalyzer  Biosystems  A25.  Data  analysis  was  performed  using  SPSS  version  20.0  statistical
analyzer,  and  respecting  ethical  diabetics.
The  main  results  are  1.97%  diabetic  and  13.85%  pre-diabetic.  The  LJ  phenomenon  occurred
with 6.45%  (alteration  in  glucose  curve  after  oral  load  decreases  plasma  glucose  concentration
determination  after  60  min  and  returns  at  relatively  higher  than  the  basal  concentration  levels
at 180  min)  and  5.19%  were  poorly  studied,  including  a  >110  mg/dl  baseline  (p  =  <0.05).  We
determined  a  high  rate  of  pre-diabetic  patients  and  a  reduced  rate  of  diabetes  coincident  with
Qiao et  al.  We  highlight  the  usefulness  of  the  OGTT,  which  must  be  rigorously  evaluated,  and
reafﬁrm the  importance  of  the  LJ  phenomenon  as  it  may  interfere  with  the  ﬁnal  results  of
unsolved events,  and  evidence  the  importance  of  interindividual  biological  variability.
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Table  2  Diagnostic  criteria  for  DM.9
1.  AlC  ≥  6.5%.  The  test  should  be  performed  in  a  laboratory
using  a  method  that  is  NGSP  certiﬁed  and  standardized  to
the DCCT  assay.a
OR
2.  FPG  ≥  126  mg/dl  (7.0  mmol/l).  Fasting  is  deﬁned  as  no
caloric intake  for  at  least  8  h.a
OR
3.  2-h  plasma  glucose  ≥  200  mg/dl  (11.1  mmol/l)  during  an
OGTT.  The  test  should  be  performed  as  described  by  the
World  Health  Organization,  using  a  glucose  load
containing  the  equivalent  of  75  g  anhydrous  glucose
dissolved  in  water.a
OR
4.  In  a  patient  with  classic  symptoms  of  hyperglycemia  or
hyperglycemic  crisis,  a  random  plasma
glucose  ≥  200  mg/dl  (11.1  mmol/l).
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ntroduction
iabetes  mellitus  (DM)  is  a  metabolic  disorder  that  is  a
onsequence  of  the  deﬁciency  in  the  secretion  of  insulin,
n  the  effectiveness  of  its  actions,  or  both.  It  is  one  of
he  most  prevalent  chronic  diseases  in  the  world.  It  con-
titutes  a  public  health  problem  due  to  the  progressive
ncrease  of  its  incidence,  to  the  point  where  it  is  consid-
red  an  epidemic.1 Chronic  hyperglycemia  with  disturbances
n  the  metabolism  of  carbohydrates,  fats  and  proteins,  and
lterations  in  microcirculation  are  all  consequences  of  this
isorder.  Current  DM  classiﬁcation  according  to  the  Ameri-
an  Diabetes  Association  --  ADA  --  is  shown  in  Table  1.
About  63%  of  the  57  million  deaths  in  the  world  in  2008
ere  caused  by  a  non-transmissible  chronic  disease,  includ-
ng  diabetes  mellitus;  thus,  80%  of  these  deaths  occurred
n  low  and  medium-income  countries.2 By  the  year  2000,
bout  171  million  people  suffered  from  DM  around  the  world,
nd  this  number  is  estimated  to  go  up  to  336  million  by  the
ear  2030.3,4 On  the  other  hand,  approximately  197  million
eople  worldwide  suffer  from  glucose  intolerance  --  pre-
iabetic  patients,  which  usually  leads  to  obesity.  Around  90%
f  type  II  diabetes  is  attributable  to  overweightness  and  to
he  metabolic  syndrome.  This  number  is  also  expected  to
ncrease  to  420  million  by  the  year  2025.5 In  addition,  the
uman  and  ﬁnancial  costs  of  DM  are  also  on  the  rise.6
A  similar  situation  occurs  in  Peru,  where  TIIDM  preva-
ence  (TIIDM)  ranges  from  1  to  8%,  Lima  and  Piura  being  the
ost  affected  regions.7 In  conclusion,  DM  is  a  health  problem
round  the  world,  one  that  is  threatening  to  reach  pandemic
evels  by  2030,  with  alarming  increases  of  TIIDM  among  chil-
ren  and  with  potentially  devastating  consequences.5
DM  is  associated  with  an  increase  in  risk  of  premature
eath;  thus,  every  year  almost  4  million  deaths  are  caused
irectly  by  this  disease.  80%  of  these  occur  in  underdevel-
ped  countries,  constituting  6.8%  of  overall  mortality.8
DM  diagnostic  methods  are:  random  glucose  test
200  mg/dl  over  clinical  symptoms,  fasting  plasma  glucose
est  >126  mg/dl,  oral  glucose  tolerance  test  (OGTT)  after  a
ast,  and  glycosylated  hemoglobin  test  A1c  ≥  6.5%  (Table  2).9
he  test  most  frequently  used  is  the  OGTT,  used  in  clinical
ractice  for  glycemic  and  insulin  diagnoses.10--12 Moreover,
Table  1  Classiﬁcation  of  DM.9
I.  Type  1  diabetes
A. Immune-mediated
B. Idiopathic
II. Type  2  diabetes
III.  Other  speciﬁc  types
A.  Genetic  defects  of  -cell  function
B.  Genetic  defects  in  insulin  action
C. Diseases  of  the  exocrine  pancreas
D.  Endocrinopathies
E. Drug-  or  chemical-induced
F.  Infections
G.  Uncommon  forms  of  immune-mediated  diabetes
H. Other  genetic  syndromes  sometimes  associated  with
diabetes
IV. GDM
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should be conﬁrmed by repeat testing.
t  is  the  most  sensitive  method  for  the  diagnosis  of  DM
ithin  the  fasting  glycemic  test,  although  it  requires  char-
cteristics  for  its  implementation,  such  as  fasting  basal
lycemia  <  110  mg/dl,  doses  of  75  g  anhydrous  glucose  in
dults  or  1.75  g/kg  for  children,  performance  in  the  morn-
ng  after  a  10--16  h  fast,  the  duration  of  the  test  is  180  min,
tc.13 One  of  the  main  disadvantages  of  OGTT  is  its  repro-
ucibility,  thus  it  is  recommended  to  have  at  least  2  patho-
ogical  OGTTs  when  basal  glycemia  is  under  110  mg/dl.14
Moreover,  inter-individual  variabilities  have  been
escribed  according  to  glucose  metabolism,  which  generate
lants  in  the  interpretation  of  clinical  criteria  that  ought  to
e  estimated.  According  to  Clinical  Laboratory  Standards
nstitute  (CLSI),  the  resultant  parameters  of  OGTT  should
e  assessed  as  the  area  under  the  curve  of  glucose  (AUCG)
nd  insulin  (AUCI)  basal  indexes,  the  maximum  allowable
rror,  among  others,  mainly  to  determine  the  sensitivity  to
eripheral  insulin.9,15--18 After  an  oral  glycemia  overload,
he  increase  in  glycemia  does  not  depend  solely  on  glucose.
here  are  also  intestinal  hormones  involved,  the  speed
f  gastric  emptying  and  the  composition  of  the  intake.
hus,  tolerance  to  glucose  and  sensitivity  to  insulin  are
ifferent  concepts,  making  the  indexes  of  correction  and
valuation  of  glycemic  sensitivity  necessary  to  guarantee
he  quality  of  the  results  and  explain  the  recurrence  of
hese  phenomena.18
Having  said  that,  the  objective  of  this  study  was  to  eval-
ate  the  criteria  for  interpretation  of  OGTT  in  the  Hospital
acional  Docente  Madre-Nin˜o  ‘‘San  Bartolomé’’  (HONADO-
ANI  SB)  in  Lima,  Peru,  and  determine  the  percentages
f  pre-diabetic  patients,  those  who  should  not  have  been
ncluded  within  the  test  (basal  glucose  >  110  mg/dl)  and
hose  who  presented  alterations  in  the  curve  of  glucose
uring  biochemical  determinations.
aterials and method non-experimental,  prospective  cross-sectional  analytic
tudy  was  conducted.
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Population  and  sample
Population
The  population  consisted  of  all  ambulatory  patients  referred
to  us  by  agreement,  at  HONADOMANI  SB.
Sample
Blood  samples  referred  from  outpatient  clinics  indepen-
dently  from  the  Department  of  Help  to  diagnosis  at
the  Biochemistry  Department  for  glycemia  determination
though  OGTT,  which  complies  with  the  quality  criteria
according  to  CLSI  Guide  POCT12-A3,  the  ADA’s  guidelines
and  the  recommendations  for  the  laboratory  analysis  of
DM  diagnosis  and  management  and  the  standardized  oper-
ational  procedures  --  SOP  --  of  the  health  center.19,20 These
are  selected  respecting  the  following  previously  established
criteria  of  inclusion  and  exclusion.
Inclusion  criteria.  Patients  (male  and  female)  in  a  fasting
state  of  at  least  10  h,  ages  ranging  from  18  to  65  years
of  age,  stable,  without  a  stress  condition,  pharmaceutical
consumption,  or  debilitating  situations  like  surgery.  Also,
patients  were  required  to  complete  the  test  (180  min,  3
blood  collections)  post-glycemic  overload.  The  collection  of
samples  must  comply  with  the  quality  guidelines  previously
mentioned.
Exclusion  criteria.  Patients  who  did  not  comply  with  the
fasting  state  of  at  least  10  h.  Patients  outside  the  age
range  (19--65  years  old).  Patients  who  were  suffering  from
a  debilitating  or  oncological  situation,  or  undergoing  phar-
macological  therapies.  Those  patients  who  left  the  test  or
complicated  blood  collections.  Those  samples  which  were
collected  without  following  the  quality  and  normativity
criteria  of  CLSI  or  ADA,  in  addition  to  samples  which  were
clearly  contaminated.
Data  collection  techniques  and  sample  processing
Pre-analytic  stage
The  collection  was  conducted  in  the  Phlebotomy  area  of
the  HONADOMANI  SB  between  6  am  and  9  am,  using  BD
Vacutainer® (Franklin  Lakes,  New  Jersey,  USA)  of  3  ml,  with
a  red  cap  which  was  mixed  by  inversion  of  8--10  times,
according  to  the  CLSI  H03-A6  guide.  In  order  to  achieve  this,
patients  must  have  remained  fasting  for  at  least  10  h  prior
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Figure  1  Results  of  1271  samplings  of  glycemia  in  the  HONADOMANI
and pre-diabetic  (glycemia  at  2  h  between  110  and  199  mg/dl)  patiese  tolerance  test  149
o  the  collection,  with  a  payment  slip  from  the  previous  day
f  the  test,  and  with  a  lemon  and  a  disposable  cup.21
The  ﬁrst  sample  (basal)  was  used  to  evaluate  the  admis-
ion  of  patients  to  the  test,  excluding  those  who  were
bove  100  mg/dl.  Subsequently,  they  were  overloaded  with
ral  glucose  (anhydride  preparation:  ‘‘lemonade’’)  using  the
ollowing  formula;  75  g  of  anhydride  glucose  for  adults  or
.75  g/kg  for  children.  The  patient  was  monitored  for  the
hole  duration  of  the  test  (180  min).  The  samples  were
ollected  at  60  and  180  min  after  the  glycemic  overload.
onventional  cohort  values  were  used  at  >200  mg/dl  for
iabetics  and  those  indicated  by  the  World  Health  Organi-
ation  (WHO)  for  the  diagnosis  of  pre-diabetic  patients  of
00--199  mg/dl  (impaired  glucose  tolerance).22--24
nalytic  stage
he  processing  in  the  clinical  lab  was  conducted  follow-
ng  the  algorithm  established  by  the  hospital  for  OGTT.
his  includes  the  reception  and  registration  of  the  sam-
le  through  the  standardized  code  and  its  processing  within
20  min  after  the  sample  was  drawn.  The  biochemical
rocessing  was  conducted  through  the  Biochemical  Biosys-
ems  A25  auto-analyzer  (Pennsylvania,  USA),  which  has  a
aily  and  historic  registry  of  biochemical  analyses.  The
ethod  employed  for  the  determination  of  glucose  was  glu-
ose  oxidase-peroxidase  through  the  glucose  activity  test
rinder.25
ost-analytic  stage
ndetermined  results  or  those  which  were  outside  the  lin-
arity  of  the  trial  were  repeated  and/or  diluted.  The  results
alidated  by  Medical  Technologists  were  inputted  into  the
ntegrated  health  system  --  SIGOS  --  to  inform  patients  within
he  stipulated  times.
ata  analysis  technique
ata  analysis  was  performed  in  three  basic  processes:
odiﬁcation,  from  the  Biochemical  Biosystems  A25  auto-
nalyzer’s  historical  registries  system;  tabulation,  statistical
eriﬁcation  and  the  creation  of  charts  and  tables  using  the
tatistical  analyzer  SPSS  20.0  and  Microsoft  Ofﬁce  Excel  2010
or  Windows.  The  evaluation  of  the  distribution  of  variables
as  conducted  using  KMO  and  Bartlett’s  test  of  sphericity,
esulting  in  a  matrix  of  correlations  between  adequate  varia-
les  (p  =  <0.05).
.00% 12.00% 14.00%
Prediabetics
LJ phenomenon
Basal glucose >110 mg/dl
Diabetics
 SB.  Also,  the  proportion  of  diabetic  (glycemia  at  2  h  >200  mg/dl)
nts  diagnosed  through  the  OGTT.
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Figure  2  Percentages  of  pre-diabetic  and  diabetic  patients.
The radial  distribution  of  patients  wrongly  included  in  the  test
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thics
ithin  the  diabetic  ethics  framework,  the  safeguarding,
eliability  and  irreplaceable  value  of  the  obtained  informa-
ion  will  only  be  used  for  the  purposes  of  this  study.  This
esearch  has  the  approval  of  the  Department  of  Teaching  and
id  for  Research  and  the  Ethics  and  Research  Commission  of
he  HONADOMANI  SB  (Reg.  78-2015).
imitations
everal  limitations  should  be  taking  into  account  before
nterpreting  the  results.
First,  the  biochemical  auto-analyzer  informatics  reg-
stry  does  not  have  detailed  registries  or  information  of
he  selected  patients,  such  as  age,  gender,  attributable
isk  factors,  physiological  condition,  diseases,  demo-
raphic  characteristics  and  family  history,  etc.  Second,
he  determination  of  glycemia  varies  considerably  between
emographics  and  age  groups.  Thus,  the  pre-diabetic  and
iabetic  prevalence  rates  encountered  are  not  transposed
oward  the  general  population  of  Peru.  Third,  the  OGTT
esults  could  not  be  compared  to  the  standard  refer-
nce  tests  like  Hb1Ac,  to  determine  its  variability  and
naccuracy.26 Lastly,  the  biochemical  processing  was  per-
ormed  under  an  internal  and  external  quality  control;
owever,  without  a  quality  responsible  planning.
Despite  these  limitations,  our  research  is  the  ﬁrst  to  eval-
ate  the  resultant  parameters  of  the  OGTT.
esults
rom  the  conducted  research,  1.97%  of  patients  were
iabetic,  13.85%  were  pre-diabetic,  6.45%  produced  the
‘LowJump’’  (LJ)  glucose  reduction-rise  phenomenon  (alter-
tion  of  the  glucose  curve  post-oral  overload  which  tends
o  reduce  the  concentration  of  plasma  glucose  in  its  deter-
ination  at  60  min  and  returns  to  relatively  superior  levels
o  the  basal  concentration  at  180  min),  and  5.19%  of  the
atients  should  not  have  been  included  in  the  study  due
o  the  fact  that  they  did  not  have  over  110  mg/dl  of  basal
lucose  (p  =  <0.05)  (Fig.  1).11,27
iscussion
he  evaluation  of  OGTT  interpretation  criteria  exposes  an
levated  rate  of  pre-diabetic  patients  and  a  reduced  rate
f  diabetics,  which  in  conjunction  constitute  15.8%  of  the
revalence  (Fig.  2).
The  prevalence  of  diabetic  patients  determined  in  this
esearch  was  half  of  that  communicated  in  the  last  report
f  DM  prevalence  in  Lima  and  Callao,  Peru  (3.9%).28 The
revalence  rate  discovered  is  somewhat  similar  to  urban
verages  in  populations  over  3000  asl.  (Huaraz  --  1.3%).23
M  is  a  chronic,  degenerative,  progressive  but  manageable
isease.  It  has  a  great  impact  on  the  economy  of  the  health-
are  system.  It  requires  serious  control  and  a  reasonable
tratiﬁcation  of  its  systemic  complications.
In  the  same  way,  the  proportion  of  patients  who  were
re-diabetic  or  had  a  high  risk  of  diabetes  or  glucose
ntolerance  was  13.85%;  prevalence  within  the  regional
verage  is  between  5  and  15%.29 Glucose  intolerance  is
 risk  factor  for  the  development  of  TIIDM  and  implies  a
s
5
t
is shown  in  Fig.  3,  highlighting  the  values  of  the  second  glycemia
ampling  in  comparison  to  the  ﬁrst  and  the  third.
igh  cardiovascular  risk.30,31 In  our  country,  the  reported
revalence  is  up  to  90.8%  in  patients  who  are  50  years
nd  older,  a  highly  elevated  prevalence,  suggesting  the
mmediate  prioritization  of  health  care  attention  in  order
o  avoid  future  complications.32
The  progression  from  normoglycemia  to  diabetes  may
ake  several  years,  which  involves  intermediate  stages  of
ysglycemia.  This  atero-thrombogenic  alteration  becomes
vident  with  the  alteration  of  glucose  when  fasting,
mergence  of  glycated  proteins  and  progressively  cel-
ular  hypofunction,  increasing  the  risk  of  morbidity  in
atients.33,34 Thus,  diabetes  indicates  a  decrease  in  the
ancreatic  reserve  (up  to  50%  when  there  is  no  diabetic
anifestation),  this  previous  metabolic  stage  is  evident  by
lycemia  between  100  and  199  mg/dl  by  the  OGTT,  which
erves  as  a  red  ﬂag  to  avoid  its  progression  to  DM.24 Inter-
ention  in  pre-diabetic  patients  is  an  efﬁcient  strategy,  since
t  avoids  or  slows  down  the  progressive  deterioration  of
he  pancreas.  This  strategy  includes  an  efﬁcient  diagnosis,
odiﬁcation  in  lifestyles,  body  weight  management,  ranges
rom  45  to  65%  of  daily  energetic  intake,  physical  exercise,
harmacological  treatment,  detection  algorithms,  etc.18 In
his  manner,  it  is  demonstrated  and  conﬁrmed  that  the  con-
rol  of  glycemia  is  an  effective  measure  to  reduce  the  load
f  microvascular  and  cardiovascular  complications,  such  as
etinopathy,  nephropathy  and  neuropathy  in  patients  with
IDM  as  well  as  TIIDM.35--37
The  main  complication  in  the  misguided  selection  of
atients  for  OGTT  is  the  dizzy  feeling  and  loss  of  con-
ciousness  during  the  glycemic  overload.  We  found  that
.19%  of  patients  should  not  have  been  included  in  the
est  (Fig.  3).  It  may  be  a minimum  ﬁnding,  however,  it
s  of  relevance  given  the  fact  that  the  lab  procedures
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Figure  3  Radial  distribution  of  patients  wrongly  included  in  the  OGTT.  Observe  the  elevated  values  in  the  second  sampling  (red
line/thicker  line).  Glycemic  concentration  is  expressed  in  mg/dl.  (For  interpretation  of  the  references  to  color  in  this  ﬁgure  legend,
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are  standardized,  and  follow  internationally  established
ﬂowcharts  which  rule  under  a  quality  control  system.  More-
over,  the  diagnosis  of  over  half  of  these  patients  was
dysglycemia  (3.2%),  1.5%  were  diabetics  and  only  0.5%  were
healthy  patients.9,11,12,15,16 Considering  that,  these  mistakes
in  patient  selection  are  a  result  of  the  generally  poor  knowl-
edge  of  the  personnel  on  these  investigations,  work  over-
load,  or  the  fact  that  there  is  no  other  diagnostic  method.
Thus,  the  modiﬁcation  of  inclusion  criteria  of  patients  in
the  OGTT,  POE,  should  be  considered  and  rely  on  the  CLSI
POCT12-A,  Clinical  Laboratory  Improvement  Amendments,
(CLIA),  ADA  guidelines,  etc.  Also,  the  use  of  other  diagnos-
tic  methods  (i.e.  the  A1c  Glycosylated  Hemoglobin  test),
evaluating  their  sensitivity,  disadvantages  and  costs.
Lastly,  we  reafﬁrm  the  importance  of  the  LJ  phenomenon
in  the  interpretation  of  the  OGTT,  because  it  could  interfere
in  the  ﬁnal  results.  From  the  ﬁnal  reports  of  this  phe-
nomenon  1.2%  were  dysglycemic  in  ranges  of  100--175  mg/dl
(Fig.  1),  which  leads  us  to  consider  its  involvement  in  the
development  of  the  trial  and  interferences  with  glycemia
--  increasing  it  or  reducing  it  --  generating  undetermined
results,  or  even  worse,  false  results.24This  ﬁnding  proves  the  importance  of  inter-individual
biological  variability,  evident  by  the  events  through  which
it  may  occur,  like  different  physiological  conditions,
metabolism  of  the  saturation  of  glycemia,  type  of  anhydride
F
Tlucose,  population  group,  diabetics,  physiological  condi-
ions  where  typologies  of  the  individuals,  pre-diabetics,  or
ther  non-clear  situations  occur.  Thus,  it  is  necessary  to
valuate  its  reach  in  interference,  to  establish  its  total
llowable  error  and  understand  the  biochemistry  and  cel-
ular  behavior  during  the  development  of  the  test  among
ndividuals.
Furthermore,  a  judicious  monitoring  is  required  in  order
o  understand  and  know  its  physiology  and  the  events
hrough  which  it  occurs,  corresponding  to  the  different
etabolisms  during  the  test  and  their  diagnostic  implica-
ions.  We  deﬁnitely  suggest  that  other  glycemia  tests  should
e  conducted  in  a  patient  where  this  phenomenon  is  discov-
red,  (Hb1A1c,  etc.)  or  repeat  the  OGTT  twice.11
Diabetes  mellitus  is  a  metabolic  disease  which  imposes  a
igh  economic  and  social  cost  around  the  world,  hence  its
revention  and  treatment  should  be  considered  imperative
n  health  and  a priority  worldwide.  The  diagnosis  should  be
horoughly  examined,  from  the  selection  of  patients  to  the
etermined  ranges  of  glucose  in  each  collection,  with  the
urpose  of  avoiding  undetermined  results  or  false  negatives.unding
his  study  was  self-ﬁnanced  by  the  authors.
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